Miraca Holdings Incorporated operates in the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Miraca Holdings Incorporated with three other
pharmaceutical manufacturers in Asia:
Dr. Lal PathLabs Ltd
sales of 9.12 billion Indian Rupees [US$141.97 million]
of which 100%
(111.24 billion Japanese Yen [US$993.40 million]
of which 95%
was Testing business), and
Falco Holdings Co Ltd
(45.97 billion Japanese Yen [US$410.52 million]
of which 61%
was Medical Test).
Miraca Holdings Incorporated reported sales of ¥204.25 billion (US$1.82 billion)
March of 2017.
decrease of 3.5%
versus 2016, when the company's sales were ¥211.74 billion.
Contributing to the drop in overall sales was the 6.7% decline
in Clinical Medical Check, from ¥45.79 billion to ¥42.70 billion.
There were also decreases in sales in
Clinical Examination (down 3.1% to ¥132.94 billion)
Healthcare (down 0.8% to ¥28.61 billion)